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The aim of this study was to evaluate the relationship between the level of total serum IgE and
the prognosis of allergic fungal sinusitis, possibility of recurrence and level of aggressiveness.
This study was a prospective controlled one.

Patients and methods

Forty patients who were diagnosed as having allergic fungal sinusitis were randomly divided
into two equal groups. One group (group A) received postoperative systemic steroids, whereas
the other group (group B) received postoperative local steroids only. The patients were followed
up for 6 months with endoscopy and IgE level evaluation.

Results

The total number of patients who had recurrence of the disease 6 months postoperatively
was 17. Six of them were from group A (systemic steroids) and 11 were from group B (local
steroids only).

Conclusion

Allergic fungal sinusitis should be treated with minimal surgical or endoscopic procedures,
followed by local and more important systemic steroids for a prolonged period. Patients should
be followed up at close intervals postoperatively using nasal endoscopy and more importantly
serum IgE (total and if available fungus specific) as it is a good indicator to the future possibility
of recurrence and thus the possibility of resurgery or further medical treatment.
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Introduction
Allergic fungal sinusitis (AFS) is characterized by
chronic hypertrophic rhinosinusitis with fungal hyphae
growing within inspissated allergic mucin obstructing
the sinus cavities. The fungal process involved in allergic
fungal sinusitis is nontissue-invasive, representing an
allergic, not infectious, disorder. Dematiaceous fungi
are the most common offending organisms, with
Bipolaris spicifera found most often [1].
The immunologic basis for AFS is thought to involve a
fungal-specific immediate hypersensitivity (IgE) reaction
as well as other antibody responses to the fungus. AFS
serologies have been suggested to be partly analogous
to allergic bronchopulmonary aspergillosis and include
fungal-specific IgG and fungal-specific IgE [2].
The past two decades have been momentous in
advancing our understanding of the role of antibodymediated immunity (AMI) in host defence against
fungi, and they have brought about a paradigm shift in
our thinking on this question. Before the 1990s, AMI
was considered to be irrelevant in host defence against
fungi, as the experimental methods that were in use at

the time were not able to consistently establish a role
for AMI [3].
Only two decades ago, antibodies to fungi were
thought to have little or no role in protection against
fungal diseases. However, subsequent research has
provided convincing evidence that certain antibodies
can modify the course of fungal infection to the benefit
or detriment of the host. Hybridoma technology was
the breakthrough that enabled the characterization
of antibodies to fungi, illuminating some of the
requirements for antibody efficacy [4].
In this study, our aim was to evaluate the relationship
between the level of total serum IgE and the prognosis
of allergic fungal sinusitis, possibility of recurrence and
level of aggressiveness, as well as the effect of steroid
therapy on the level of IgE and its impact on recurrence
rates and aggression.
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Patients and methods
This prospective study (randomized control study) was
performed in the Otorhinolaryngology Department,
Kasr El-Aini Hospital, Cairo University (Cairo,
Egypt), during the period from July 2013 to January
2015. This study has been approved by the ethical
committee. It included 40 patients who were diagnosed
at the outpatient clinic as having AFS.
These patients were diagnosed as having AFS according
to the major and minor criteria. Two major with two
minor criteria were sufficient for diagnosis.
Major criteria

•
•
•
•
•

Presence of nasal polyps with allergic mucin
IgE-mediated hypersensitivity
Characteristic computerized tomographic scan
features
Eosinophilic nasal mucosa
Noninvasive fungal colonies on smear, culture, or
histopathology.

Minor criteria

•
•
•
•
•

History of bronchial asthma
Unilateral predominance of polyps
Eosinophilia in peripheral smear
Charcot–leyden crystals on histopathology
Radiographic bone erosion.

All patients with allergic fungal sinusitis (denovo or
recurrent) and patients of all age groups and geographic
and demographic distributions were included. Only
patients with immunocompromised state and patients
who were found to have tissue invasion were excluded.
The 40 patients who were included in this study were
randomly divided into two groups (20 patients in each
group). Patients in the first group (group A) received
systemic steroid therapy postoperatively, whereas
patients in the other group (group B) did not receive
systemic steroids and were only given local steroids as
postoperative therapy.
All patients were subjected to clinical assessment,
including a thorough physical examination,
nasoendoscopy (Fig. 1), routine preoperative laboratory
investigations, preoperative anaesthetist consultation
and full history taking from patient. All patients
were counselled about the plan of management and
procedure, and a signed written consent form of
approval was obtained from patients.
Level of IgE (total) was evaluated in serum. Patients
were managed accordingly. All patients needed surgical
intervention ranging from middle meatal antrostomy

to ethmoidectomy and sphenoidotmy. All procedures
were performed by the same surgeon. All procedures
were performed endoscopically under general
anaesthesia.
Patients stayed at the department for 2 days
postoperatively. Non-narcotic pain killers were
administered in the postoperative period. The nasal
packs were removed and the patients were discharged
on medical treatment according to the grouping.
Patients in group A who received oral steroid therapy
were administered oral prednisolone at a dose of
80 mg daily for 2 weeks, which was tapered over a
further period of 2 weeks. All patients received oral
ranitidine 150 mg once daily with the systemic steroid,
and fluticasone propionate nasal spray at a dose of
two puffs once daily. Patients in group B received
fluticasone propionate nasal spray only at the same
dose as group A.
At the time of recruitment, enquiry was made as
regards the presence of nasal obstruction, nasal
discharge, sneezing, hyposmia or anosmia, headache,
facial pain, visual disturbances and change in facial
features. At 3 months and again at 6 months following
recruitment, enquiry was made again as regards these
symptoms.
Patients were followed up postoperatively at 3 and
6 months. In the outpatient clinic, patients were
examined by means of anterior rhinoscopy and nasal
endoscopy, searching for polypi, allergic mucin or
fungal masses. Moreover, new computed tomography
(CT) scans were performed to evaluate the current
state of the nose and sinuses radiologically.
Kupferberg’s prognostic endoscopic mucosal staging
system for diagnosing recurrence of AFS has been
followed as the standard parameter in the follow-up
care of postoperative AFS patients [5]. This staging
system comprises of the following:
Figure 1

a

b

Endoscopic picture of allergic fungal sinusitis patients showing (b)
polyps and (a) allergic mucin.
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Stage 0: No evidence of disease.
Stage 1: Oedematous mucosa with allergic mucin.
Stage 2: Polypoidal mucosa with allergic mucin.
Stage 3: Polyps with allergic mucin and fungal
debris.

Furthermore, patients with more than 10% increase
in serum IgE could be divided according to the
aggression of the recurrence as follows: (i) 10–30%,
mild recurrence, (ii) 30–50%, moderate recurrence and
(iii) more than 50%, severe recurrence of the disease.

This last stage signals the recurrence of disease and
necessitates surgical reintervention.

The results obtained were statistically analysed
as follows: descriptive output (group A,
Tables 1 and 2; group B, Tables 3 and 4) and relations
output (Tables 5–10).

The levels of serum IgE (total) were also evaluated at
3 and 6 months postoperatively. The prognosis of the
patients was evaluated at 3 and 6 months to screen for
recurrence and evaluate aggressiveness and its relation
with the level of IgE and systemic steroid therapy.
All data were collected and statistical analysis was
performed on an intention-to-treat basis. Comparison
of the two groups was made in terms of levels of total
serum IgE, presence of recurrence and aggression of
recurrence.

Results
Forty patients of those diagnosed as having AFS
accepted our plan of management and were recruited in
our study. Those were randomly divided into two groups.
Group A (20 patients) received local and systemic
steroids, whereas group B (20 patients) received local
steroid therapy only. Of the 40 patients, 25 were female
and 15 were male. All patients were within the age
group of 20–50 years, except for seven patients (five
teenagers and two patients above 50 years of age).
The total number of patients who had recurrence of the
disease after 6 months postoperatively was 17 patients.
Six of them were from group A (systemic steroids) and
11 were from group B (local steroids only). As regards
the severity and aggression of recurrence, 12 patients
had mild recurrence (five from group A and seven from
group B), four patients had moderate recurrence (one
from group A and 3 from group B) and one patient was
considered to have severe recurrence (group B).
The mere values of the serum IgE varied from one
patient to another and from one laboratory to another.
Therefore, the increase in the level of serum IgE from
3 to 6 months postoperatively was calculated, and
the percentage increase from the first value obtained
postoperatively (at 3 months) was obtained.
On obtaining the percentage increase in serum IgE, it
was found that patients with less than 10% increase in
serum IgE had no recurrence, whereas those who had
more than 10% increase in serum IgE had some sort of
recurrence of the disease.

From the previous statistical analysis we can find that
there is a significant relation between the administration
of systemic steroids and the percentage increase in the
serum IgE. The percentage increase in total serum IgE
was lower in the group receiving systemic steroids
(sometimes there was a decrease in serum IgE).
Table 1 Recurrence aggressiveness
Valid

Frequency (n (%))

None
Mild
Moderate

14 (70.0)
5 (25.0)
1 (5.0)

Total

20 (100.0)

Table 2 Recurrence possibility
Valid

Frequency (n (%))

No recurrence
Recurrence

14 (70.0)
6 (30.0)

Total

20 (100.0)

Table 3 Recurrence aggressiveness
Valid

Frequency (n (%))

None
Mild
Moderate
Severe

9 (45.0)
7 (35.0)
3 (15.0)
1 (5.0)

Total

20 (100.0)

Table 4 Recurrence possibility
Valid

Frequency (n (%))

No recurrence
Recurrence

9 (45.0)
11 (55.0)

Total

20 (100.0)

Table 5 Relation between IgE and recurrence possibility

IgE preoperative
IgE 3 months
IgE 6 months

Recurrence
possibility

N

Mean

SD

No recurrence
Recurrence
No recurrence
Recurrence
No recurrence

23
17
23
17
23

1143.48
1621.41
490.57
971.00
466.65

558.196
781.794
357.612
503.605
387.575

Recurrence

17

1240.76

717.399
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Table 6 Relation between IgE and the steroid groups
IgE preoperative

IgE 3 months

IgE 6 months

Figure 2

Groups

N

Mean

SD

Group A receiving
systemic steroids
Group B receiving
local steroids
Group A receiving
systemic steroids
Group B receiving
local steroids
Group A receiving
systemic steroids

20

1468.30

789.640

20

1224.90

581.618

20

590.35

512.450

20

799.15

441.419

20

622.00

641.899

Group B receiving
local steroids

20

969.30

663.410

Group recurrence.

Table 7 Relation between increase in IgE in percent and
steroid groups
Increase in IgE in
percent

Group

N

Mean

SD

Group A receiving
systemic steroids

20

−8.15

40.056

Group B receiving
local steroids

20

15.35

18.715

Table 8 Relation between increase in IgE in percent and
recurrence possibility

Increase in IgE in
percent

Recurrence
possibility

N

Mean

SD

No recurrence

23

−12.74

33.632

Recurrence

17

25.71

14.426

Table 9 Relation between IgE and recurrence aggressiveness
ANOVA

Significance

IgE preoperative
IgE 3 months

Between groups
Between groups

0.175
0.004

IgE 6 months

Between groups

0.000

ANOVA, analysis of variance.

It was also found that there is a significant relation
between administration of systemic steroids and the
possibility of recurrence, whereas the relation with the
degree of recurrence was not so significant.
Furthermore, it was found that there is a significant
relation between the % increase in serum IgE and the
possibility and severity of recurrence. The higher the %
increase in serum IgE, between 3 and 6 months, the
higher the possibility of recurrence and the more the
aggression of the recurrence (Fig. 2).

Discussion
Recent evidence supports the theory that allergic fungal
rhinosinusitis (AFRS) represents an immunologic,
rather than a infectious, disease process. An improved
understanding of this underlying disease process has
led to an evolution in the treatment of AFRS [6].

Medical therapy has begun to shift from an emphasis on
systemic antifungal therapy to various forms of topical
treatment and immunomodulation. Likewise, surgical
treatment of AFRS, still a crucial component of the
overall treatment plan of the patient, has shifted from
radical to a more conservative, yet complete, approach.
In our series, all patients underwent endoscopically
by the same surgeon. Although important, surgery
alone does not lead to a long-term, disease-free state.
A comprehensive management plan incorporating
both medical and surgical care remains the most likely
way to provide long-term disease control for AFRS [6]
and this is the management plan we followed in our
study.
Waxman et al. [7] were one of the first researchers to
suggest that oral steroid therapy should be initiated
in the immediate postoperative period after complete
surgical extirpation of the disease. The role of surgery
was to decrease the antigen load by removing the fungus
entrapped in allergic mucin and improve drainage of
the sinuses, whereas that of steroid was to decrease the
inflammatory response and polyposis. They described a
good response in seven patients who were administered
this therapy. Soon similar reports followed. Our results
also showed good response in patients of group A.
Out of 20 patients, only six patients had recurrence on
follow-up, compared with 11 in group B.
Kupferberg et al. [5] recommended oral prednisolone
at a dose of 40 mg/day for 4 days, 30 mg/day for 4 days
and 20 mg/day for 1 month. The dose was then adjusted
to the lowest possible dose at which the patient could
be maintained at stage 0. Using this protocol, the
authors studied 26 adult patients with AFS, of whom
12 received oral steroid. Six (50%) of these patients
were maintained at stages 0 and 1, whereas only one
out of 14 others who had not received oral steroid was
at stage 0. The beneficial effect of oral steroid was found
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Table 10 Relation between increase in IgE in percent and
recurrence aggressiveness
ANOVA
Between groups

Significance
0.000

ANOVA, analysis of variance.

to be statistically significant (P = 0.04). Dosages of less
than 15 mg/day on alternate days led to recurrence,
suggesting that prolonged maintenance steroid therapy
was essential. In our study, patients who received oral
steroid therapy were administered oral prednisolone at
a dose of 80 mg daily for 2 weeks, which was tapered
over a further period of 2 weeks. In all, 14 of those
patients were maintained disease free after 6 months
postoperatively (P < 0.01).
Kupferberg et al. [5] also suggested a prolonged
maintenance dose of oral steroid to prevent
recurrence. In a recent study, after the initial course
of oral steroid, maintenance of sinus mucosa at
stage 0 was possible with inhaled steroid alone.
However, two patients in the oral steroid group
with a follow-up of 9 months and 1 year developed
recurrence (endoscopic stage 3) when they stopped
all therapy for 2 months before presentation. This
suggests the need for prolonged surveillance and
maintenance with inhaled steroid even in those who
have responded completely initially, which is similar
to our recommendations when comparing our results
with other studies covering a longer postoperative
period of time.
Rupa et al. [8] suggest that oral steroid therapy with
inhaled steroids administered for at least 3 months
following successful sinus surgery is effective in
controlling disease and preventing early recurrence in
patients with AFS. Recurrence of disease could occur
in those who do not continue prolonged maintenance
therapy with oral and/or inhaled steroid. The speed of
recurrence is, however, variable and needs further study.
A comprehensive management plan incorporating
both medical and surgical arms remains the most likely
way to provide long-term disease control of AFS [1].
This was the plan of management in our study too,
surgical and medical treatment together with frequent
nasal douches.
In our series, all 40 patients were essentially treated
surgically. Only endoscopic approaches were
used, ranging from middle meatal antrostomy to
ethmoidectomies and sphenoidotomy, depending
mainly on the extent of the disease. Moreover,
the surgeon’s preference was the deciding factor.
All procedures were performed under general
anaesthesia.
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AFS tends to be recurrent and resistant to antimicrobial
treatment with numerous surgical procedures being
the rule. No treatment modality has proved to be
consistently effective. Kupferberg and Bent [9]
recommended that patients should be examined
monthly for an indefinite period. Physical signs
usually appear before clinical symptoms. In our study,
patients were followed up every 3 months with serum
IgE and nasal endoscopy. If any physical findings or
elevated levels of total serum IgE were encountered,
noncontrast CT scans were performed.
The main reasons for recurrence are inadequate initial
debridement, irregular follow-up and not cleaning
the postoperative cavities. Careful follow-up and early
treatment of the recurrent disease may salvage some
patients from revision surgery. In a similar study, the only
significant factors that are responsible for the recurrence
were found to be the complete opacification of the
sphenoid and the frontal sinus preoperatively [10]. In
our study, there were 17 recurrences out of 40 patients
(i.e. a recurrence rate of 42.5%). All these recurrences
were within the 6 months of the surgery. Both groups,
topical steroids and systemic steroids, had recurrences.
In our study, however, we had several similar results
to previous studies and what has been reported in
the literature, as well as some disagreeing results.
There is a statistically significant relation between the
administration of systemic steroids for a prolonged
period of time postoperatively and the level of total
serum IgE (P < 0.001). The percentage increase in
the level of total serum IgE was found to be much
less in patients receiving systemic steroids; in fact, in
several patients the level of serum IgE fell between
3 and 6 months, which means that systemic steroids
postoperatively lowers the levels of serum IgE.
Another significant finding was that there is a
significant relation between the % increase in serum
IgE levels and the possibility of recurrence and its
degree. When there was no or mild percentage increase
in serum levels of IgE, there was no recurrence at all.
The higher this, the greater the incidence of recurrence.
Moreover, the higher the percentage increase, the more
aggressive the recurrence. This means that the followup of the levels of serum IgE and the calculation of
this percentage increase over the period of follow-up
is a very useful and reliable method for predicting the
possibility of recurrence and, if present, its aggression.

Conclusion
AFS should be treated with endoscopic procedures,
followed by local and more important systemic
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steroids for a prolonged period of time. This might
be followed by long-term maintenance on local
steroids alone. Patients should be followed up at
close intervals (4 weeks) postoperatively using
nasal endoscopy and more importantly serum IgE
(total and if available fungus specific) as it is a good
indicator of the future possibility of recurrence. If
recurrence is highly suspected, CT scan is performed.
Decision could be taken accordingly on whether
resurgery or another course of systemic steroids is
needed.
We also recommend further studies on
immunotherapy in AFS, prolonged study periods
for longer follow-up of patients in the future, and
fungus-specific serum IgE evaluation to avoid
fallacies that might occur from total IgE that might
be elevated in some patients due to other atopic
conditions.
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